

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

SERIAL NO.:

SF0896K

09/768,917

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:

VICARI et al.

FILING DATE:

January 24, 2001

GROUP:

TO BE ASSIGNED

Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AW	AQ	Youseff, S. et al., 2000, "CC-Chemokine-Encoding DNA Vaccines Enhance Break down of Tolerance to their Gene Products and Treat Ongoing Adjuvant Arthritis" <i>J. Clin. Invest.</i> 106:361-371
	AR	Xin, K.Q. et al., 1999, "Immunization of RANTES Expression Plasmid with a DNA Vaccine Enhances HIV-1 Specific Immunity" <i>Clin. Immunol.</i> 92:90-96.
	AS	Sin, J. et al., 2000, "DNA Vaccines Encoding Interleukin-8 and RANTES Enhance Antigen-Specific Th1-type (CD4+) T-cell-mediated Protective Immunity against Herpes Simplex Virus Type 2 in Vivo." <i>J. Virol.</i> 74:11173-11180.
	AT	Nomura, T. et al., 2000, "Chemokines and Anti-cancer Immunotherapy" <i>Anticancer Res.</i> 20:4073-4080.
	AU	Lu, Y. et al., 1999, "Macrophage Inflammatory Protein 1 Alpha Expression Plasmid enhances DNA Vaccine-Induced Immune Response Against HIV-1" <i>Clin Exp. Immunol.</i> 115:335-341.
	AV	Lillard, J.W. et al., 1999, "Lymphotactin acts as an Innate Mucosal Adjuvant" <i>J. Immunol.</i> 162:1959-1965.



EXAMINER

DATE CONSIDERED

Dee llee

1/11/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SF0896K	SERIAL NO.: 09/768,917		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: VICARI et al.			
(Use several sheets if necessary)				FILING DATE: January 24, 2001			
				GROUP: TO BE ASSIGNED			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
De	AQ	Lehner, T. <i>et al.</i> , 2000, "Heat Shock Proteins Generate Beta-Chemokines which Function as innate adjuvants enhancing Adaptive Immunity" <i>Eur. J. Immunol.</i> 30:594-603.					
	AR	Laning, J. <i>et al.</i> , 1994, "Inhibition of in Vivo Tumor Growth by the Beta Chemokine, TCA3" <i>J. Immunol.</i> 153:4625-4635.					
	AS	Kim, J.J. <i>et al.</i> , 2000, "Chemokine Gene Adjuvants can Modulate Immune Responses Induced by DNA Vaccines" <i>J. Interferon Cytokine Res.</i> 20:487-498.					
	AT	Braun, S.E. <i>et al.</i> , 2000, "The CC Chemokine CK Beta-11/MIP-3 beta/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells through NK Cells" <i>J. Immunol.</i> 164:4025-4031.					
✓	AU	Biragyn, A. <i>et al.</i> , "Genetic Fusion of Chemokines to Self Tumor Antigen Induces Protective, T-Cell dependent Antitumor Immunity" <i>Nat. Biotechnol.</i> 17:253-258.					
	AV						
EXAMINER 				DATE CONSIDERED 			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							